4//SEC Filing
Pierce Christopher 4
Accession 0001209191-21-029352
CIK 0001678660other
Filed
Apr 29, 8:00 PM ET
Accepted
Apr 30, 6:24 PM ET
Size
9.2 KB
Accession
0001209191-21-029352
Insider Transaction Report
Form 4
Pierce Christopher
EVP and Chief of Business Oper
Transactions
- Exercise/Conversion
Employee Stock Option (right to buy)
2021-04-29−3,295→ 4,323 totalExercise: $1.89Exp: 2030-03-26→ Common Stock (3,295 underlying) - Exercise/Conversion
Common Stock
2021-04-29$1.89/sh+3,295$6,228→ 7,045 total - Sale
Common Stock
2021-04-29$40.29/sh−3,295$132,765→ 3,750 total
Footnotes (3)
- [F1]The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.02 to $40.94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
- [F3]This option is fully vested.
Documents
Issuer
Prelude Therapeutics Inc
CIK 0001678660
Entity typeother
Related Parties
1- filerCIK 0001824631
Filing Metadata
- Form type
- 4
- Filed
- Apr 29, 8:00 PM ET
- Accepted
- Apr 30, 6:24 PM ET
- Size
- 9.2 KB